Comorbid Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Current Understanding, Risk Factors, Implications for Clinical Practice, and Suggested Interventions

Managing cognitive impairment in patients with chronic obstructive pulmonary disease (COPD) in Saudi Arabia: what are the current practices?

OBJECTIVE

Cognitive impairment is a common comorbidity, yet overlooked, in patients with chronic obstructive pulmonary disease (COPD). However, little is known about the current practice and perceptions of physicians on recognising and managing cognitive impairment in patients with COPD in Saudi Arabia. This study aimed to investigate current practices and perceptions of physicians in Saudi Arabia regarding the recognition and management of cognitive impairment in COPD patients.

METHODS

An online cross-sectional questionnaire was distributed between March and October 2023 to physicians in Saudi Arabia. The collected responses were analysed using descriptive statistics.

RESULTS

A total of 808 physicians completed the online survey. Of whom, only 19% indicated receiving adequate training for managing cognitive impairment. Although the vast majority of physicians reported that cognitive impairment leads to underestimation of COPD severity (85%) and interferes with self-management (85%), only 11% agreed on the important role of screening. In addition, only half of the study participants aimed to identify possible cognitive impairment, with only 4% screening for cognitive impairment during patients' assessment. The overall confidence level in recognising and managing cognitive impairment was relatively low. The most common barriers contributing to the suboptimal management of cognitive impairment in COPD were poor training (62%), the absence of standardised procedures (63%) and limited knowledge (58%) about cognitive impairment in COPD.

CONCLUSION

The current practice of recognising and managing cognitive impairment in Saudi Arabia is suboptimal. This is likely to be attributed to inadequate training, the absence of standardised procedures, and limited knowledge about cognitive impairment in COPD. Healthcare systems should provide more training and implement a holistic approach to detect and manage cognitive impairment during patients' visits.

Prevalence and Risk Factors of Cognitive Impairment in COPD: A Systematic Review and Meta-Analysis

AIM

The aim of this systematic review is to present the pooled estimated prevalence and risk factors for cognitive impairment (CI) in patients with chronic obstructive pulmonary disease (COPD).

BACKGROUND

Patients with COPD suffer from progressive and irreversible airflow limitation, resulting in continuous impairment of lung function, which in addition to causing lesions in the lungs, often accrues to other organs as well. In recent years, a growing number of cross-sectional and longitudinal studies have shown that hypoxia is an important factor in causing CI and that there is an important link between them, but the assessment of co-morbid neurocognitive impairment and dysfunction is often overlooked. Some studies suggest that the diagnosis of mild cognitive impairment (MCI) is considered a precursor to dementia symptoms, with an annual conversion rate of 5%-10%, and it has been suggested that MCI is a potentially reversible state that can be used as a window for intervention. There is a lack of evidence on the prevalence and influencing factors of CI and its MCI.

DESIGN

A systematic review and meta-analysis.

METHODS

PubMed, Web of Science, the Cochrane Library, Ovid, Wiley, and Scopus were searched for cohort, case-control, and cross-sectional studies investigating the prevalence and risk factors of CI and MCI in COPD to June 2023 from building. Meta-analyses were performed to identify CI and MCI prevalence and risk factors using a random-effects model. The methodological quality assessment was conducted by the modified Newcastle-Ottawa Scale (NOS) and Agency for Healthcare Research and Quality (AHRQ). This study was registered on PROSPERO (CRD42021254124).

RESULTS

In total, 41 studies (21 cohort studies, 7 case-control studies, and 13 cross-sectional studies) involving 138,030 participants were eligible for inclusion. Current evidence suggests that the average prevalence of CI and MCI in COPD was 20%-30% (95% CI, 0.17-0.28) and 24% (95% CI, 0.17-0.32), respectively. Significant heterogeneity existed both in CI and MCI (I2 = 99.76%, 91.40%, p < 0.001). Mata-regression analysis showed that different region could be the source of heterogeneity in the pooled results. Cough, FEV1, PaO2, age, education, depression, and BODE index are influential factors in the development of CI in COPD.

CONCLUSION

Integrated epidemiological evidence supports the hypothesis that the prevalence of CI in the COPD population has shown an increasing trend, with differences by region and by instrument. Cough, FEV1, PaO2, age, education, depression, and BODE index are influential factors in the development of cognitive impairment in COPD patients. We should promote early screening and management of COPD patients and take targeted measures to prevent and reduce the incidence of CI.

IMPLICATIONS FOR PRACTICE

This systematic evaluation and meta-analysis identifies seven important risk factors for the development of CI among COPD patients and exposes their current epidemiological findings to provide a theoretical basis for public health administrators and healthcare professionals to effectively increase the screening rate of cognitive impairment in patients with COPD as well as to carry out early intervention.

TRIAL REGISTRATION

PROSPERO).crd. york.ac.uk.

A biopsychosocial analysis of risk factors for persistent physical, cognitive, and psychological symptoms among previously hospitalized post-COVID-19 patients

A significant number of COVID-19 survivors continue to experience persistent physical, cognitive, and psychological symptoms up to one year after discharge. This study aimed to examine the frequency, severity, and progression of and risk factors for these symptoms. This single-centre retrospective cohort study included 126 COVID-19 patients admitted to the VieCuri Medical Centre between 2020 and 2022. Follow-up assessments were conducted at 3 and 12 months postdischarge, including pulmonary function tests, CT scans, bioimpedance analysis, and questionnaires on physical, cognitive, and psychological symptoms. At both follow-up assessments, 31-32% of patients reported moderate to severe physical symptoms, 26-27% reported multiple cognitive symptoms, and 14-18% experienced depressive or posttraumatic stress symptoms (PTSSs). Only anxiety symptoms significantly decreased between the 3-month follow-up and the 12-month follow-up (from 22 to 12%; p = .014). The persistence of symptoms at 12 months was significantly associated with premorbid conditions (chronic respiratory disease, multiple comorbidities), illness severity (infection during the third wave), physical factors (COVID-19-related pulmonary abnormalities, lower total lung capacity, and dyspnoea), and cognitive and psychological factors (cognitive symptoms, anxiety, depression, and PTSS) (p < .05). These findings suggest that a significant proportion of COVID-19 survivors continue to experience persistent symptoms due to biopsychosocial factors, thus emphasizing the need for a biopsychosocial approach in early screening and treatment.

Abnormal Brain Functional Connectivity in Patients with Chronic Obstructive Pulmonary Disease and Correlations with Clinical and Cognitive Parameters

Background

Cognitive impairment is a major comorbidity of chronic obstructive pulmonary disease (COPD), but the underlying mechanisms are not fully understood. In this study, we used resting-state functional magnetic resonance imaging to investigate brain functional connectivity (FC) abnormalities in patients with COPD and explored the correlation between abnormal FC and COPD-related clinical parameters.

Methods

Forty-one patients with COPD, without a definite diagnosis of cognitive impairment or depression, and 30 age- and sex-matched controls were recruited. A total of 184 resting-state functional connectivity (RSFC) maps were generated for all seed points. Welch's t-test was used to assess differences in RSFC between the COPD and control groups, and the correlation coefficients between RSFC and clinical parameters were calculated.

Results

Patients with COPD had lower scores on the Mini-Mental State Exam (MMSE) and Korean version of the Montreal Cognitive Assessment and higher scores on the Beck Depression Inventory than the control group. Additionally, patients with COPD showed decreased RSFC in the left middle-posterior cingulate cortex, left posterior-dorsal cingulate cortex, and right superior occipital gyrus and increased RSFC in the left superior temporal sulcus, left posterior transverse collateral sulcus, right occipital pole, and right precentral gyrus. The regions showing differences in FC correlated with MMSE score, COPD symptom assessment scales, such as the COPD Assessment Test and modified Medical Research Council Dyspnea Scale, and pulmonary function parameters, including forced expiratory volume in one second and forced vital capacity.

Conclusion

Patients with COPD showed significant differences in FC within specific brain regions that correlated with symptoms, cognition, and lung function.

Construction and evaluation of nomogram for risk prediction of cognitive impairment in chronic obstructive pulmonary disease comorbidity

OBJECTIVES

Chronic Obstructive Pulmonary Disease (COPD) remains a serious public health problem globally, and the mortality rate for older COPD patients with cognitive impairment is almost three times that of older patients with cognitive impairment or COPD. The aim of this study was to construct a nomogram prediction model for the risk of comorbid cognitive impairment in COPD patients and to evaluate its clinical application. It helps to detect cognitive impairment in COPD patients at an early stage and give them effective interventions in time, so as to delay the progression of COPD patients and improve their prognosis.

METHODS

In this study, patients with COPD hospitalized at the Affiliated Hospital of North China University of Science and Technology were evaluated for cognitive function using the Montreal Cognitive Assessment(MoCA) scale after stabilization of acute exacerbations. Participants were stratified into two groups: a case group (with cognitive impairment) and a control group (without cognitive impairment), based on predefined MoCA cutoff scores(< 26scores). Based on the basic characteristics of the patients and the laboratory indexes after stabilization of acute exacerbations, we conducted statistical analyses, screened out the risk factors and established the Nomogram Prediction Model by using the R software, and finally, we evaluated the clinical value of the model through the calculation of ROC curves for sensitivity, specificity and kappa value. Finally, the sensitivity, specificity and Kappa value were calculated by ROC curve to evaluate the clinical value of the model.

RESULTS

After statistical analysis, C-reactive protein (CRP) and homocysteine (Hcy) were found to be the risk factors for combined cognitive impairment in COPD patients, and the Nomogram prediction model was constructed by combining CRP and Hcy and plotted the ROC curve, and it was found that its model finally screened the critical value of the total score of 62.55, and the area under the ROC curve of the model was 0.870, and the sensitivity was 84.7%, and the specificity was 80.4%, indicating that it has a high degree of consistency with the actual results, which indicated that the consistency between the prediction results and the actual results was better, and it had a higher clinical application value.

CONCLUSIONS

CRP and Hcy are closely associated with comorbid cognitive impairment in COPD patients after stabilization of acute exacerbations, and increased levels of CRP and Hcy are associated with an increased risk of comorbid cognitive impairment in COPD patients. Combining both CRP and Hcy to create a nomogram model for predicting comorbid cognitive impairment in patients with COPD has good predictive ability.

Gray matter and cognitive alteration related to chronic obstructive pulmonary disease patients: combining ALE meta-analysis and MACM analysis

Chronic obstructive pulmonary disease (COPD) is frequently comorbid with cognitive impairment, but it has not been paid enough attention, and its neuroanatomical characteristics have not been fully identified. Voxel-based morphometric (VBM) studies comparing gray matter (GM) abnormalities in COPD patients with healthy controls (HCs) were searched using 8 electronic databases from the inception to March 2023. Stereotactic data were extracted and tested for convergence and differences using the activation likelihood estimation (ALE) method. Moreover, based on the ALE results, a structural meta-analytic connectivity modeling (MACM) was conducted to explore the co-atrophy pattern in patients with COPD. Last, behavioral analysis was performed to assess the functional roles of the regions affected by COPD. In total, 11 studies on COPD with 949 participants were included. Voxel-based meta-analysis revealed significant GM abnormalities in the right postcentral gyrus (including inferior parietal lobule), left precentral gyrus, and left cingulate gyrus (including paracentral lobule) in patients with COPD compared with HCs. Further MACM analysis revealed a deeper co-atrophy pattern between the brain regions with abnormal GM structure and the insula in COPD patients. Behavioral analysis showed that the abnormal GM structure in the left cingulate gyrus (including paracentral lobule) was strongly associated with cognitive function, especially executive function. COPD comorbid with cognitive impairment has a specific neurostructural basis of GM structural abnormalities, which may also involve a deeper co-atrophy pattern between the insula. These findings enhance our understanding of the underlying neuropathogenesis and suggest potential imaging markers for cognitive impairment in COPD patients. PROSPERO registration number: CRD42022298722.

Addressing inhaler technique challenges in cognitively impaired chronic obstructive pulmonary disease patients: the impact of customized training programs

Individuals with chronic obstructive pulmonary disease (COPD) and cognitive impairment (CI) often face difficulties accurately administering inhalers, which are essential for managing their respiratory condition. Many elderly individuals make major errors that prevent proper medicine administration. Maintaining proper inhaler use skills is critical in controlling COPD. Our goal was to examine and evaluate the inhaler use skills of CI patients with COPD during both the initial evaluation and subsequent appointments. The Respiratory Department of KLEs Dr. Prabhakar Kore Hospital and Medical Research Centre, Nehru Nagar, Belagavi, Karnataka, India, was the site of this prospective interventional study. Based on the Montreal Cognitive Assessment Scale (MoCA), a subset of patients with COPD exhibited mild CI. Patients exhibiting improper inhaler-using skills were detected, corrected, and trained. Inhaler techniques were reassessed immediately and at follow-up visits. The modified Medical Research Council scale score (mMRC), COPD assessment test (CAT) score, St. George Respiratory Questionnaire (SGRQ), and pulmonary function tests were reassessed. A total of 56 COPD and CI patients who had made at least one significant mistake when using an inhaler device were added to the study. The mean age was 66.89±9.85 years. When evaluated with MoCA, the mean score was 17.02±3.91. At baseline, the mean number of mistakes was 1.38±0.93, which decreased to 0.54±0.57 after face-to-face demonstration of correct inhaler techniques. Correlational analysis revealed MoCA scores were negatively associated with the number of mistakes (r=-0.344). At follow-up, CAT score (25±5.61 vs. 18.48±5.24 p=0.001), SGRQ score (53.82±20.59 vs. 37.61±22.17 p=0.001), mMRC score (3.21±0.76 vs. 3.20±0.75 p=0.001), and forced expiratory volume in 1 second/forced vital capacity score (66.86±9.35 vs. 70.08±9.07 p=0.001) had significantly improved in patients demonstrating the correct technique. Pharmacist-led interventions demonstrated improvements in health-associated quality of life and therapeutic outcomes for individuals with COPD and CI. The study highlighted the importance of cognitive evaluation in routine COPD therapy, identifying potential impediments to effective therapy, and offering face-to-face presentations of inhaler techniques. The best inhalers and methods for COPD patients experiencing CI should be further investigated, according to the study.

Healthcare Workers (HCWs)' Perceptions and Current Practice of Managing Cognitively Impaired Patients with Chronic Obstructive Pulmonary Disease (COPD)

Background and Objectives: Despite the significant impacts of cognitive impairment on patients with chronic obstructive pulmonary disease (COPD), there is limited information available on healthcare workers' (HCWs) perceptions, current practice, and barriers to managing COPD patients with cognitive impairment. Materials and Methods: A cross-sectional questionnaire was distributed to HCWs in Saudi Arabia between April and December 2023. The collected responses were analysed using descriptive statistics and logistic regression models. Results: A total of 890 participants, including nursing, physical, and respiratory therapists, completed the online questionnaire. Over two-thirds of the study participants indicated not having sufficient knowledge or adequate training in managing cognitive impairment in patients with COPD. The majority of HCWs perceive cognitive impairment to underdiagnose COPD (83%), underestimate COPD severity (81%), exacerbate COPD symptoms (80%), and interfere with self-management (81%) and pulmonary rehabilitation (81%). However, less than 45% (n = 394) reported having the potential to recognise signs of cognitive impairment during patient encounters. Logistic regression analysis revealed that male healthcare practitioners were more likely to recognise cognitive impairment than females (OR: 1.48; 95% CI: 1.13 to 1.95; p < 0.001). Physical and respiratory therapists were more likely to identify cognitive impairment compared to nurses. Additionally, having more years of experience (≥10 years, OR: 1.63; 95% CI: 1.02 to 2.61; p = 0.001) and adequate knowledge of cognitive impairment (OR: 6.23; 95% CI: 4.18 to 9.29; p = 0.001) were strongly associated with better recognition. Confidence in managing cognitively impaired COPD patients was low, attributed to poor training (64%), inadequate knowledge (64%), and the absence of standardised procedures (58%). Conclusions: HCWs agreed upon the negative impacts associated with cognitive impairment in patients with COPD. However, the potential of recognising signs of cognitive impairment and confidently dealing with the existence of cognitive impairment in COPD is not optimal, owing to poor training and limited knowledge. A focus should be given to managing comorbidities alongside COPD.

Cognitive Functioning Influences Mortality Risk Among Older Adults with COPD

Background/Objeectives: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of mortality in the United States (U.S.), with rates varying by disease severity, comorbidities, and sociodemographic factors. Cognitive impairment has been independently associated with increased mortality, but has not been well studied in relation to COPD despite being a frequently overlooked comorbidity in COPD patients. The purpose of this nationwide study was to assess the relationship between low cognitive performance and the risk of mortality among older adults with COPD while adjusting for major sociodemographic and health-related characteristics.

METHODS

This study utilized the 1999-2002 National Health and Nutrition Examination Survey (NHANES) and the respiratory mortality data of noninstitutionalized US adults aged over 65 years. Survival curves showing the combined effect of cognitive decline and COPD using the Kaplan-Meier product-limit method to estimate the percent survival of the subject at each point in time were used.

RESULTS

The final sample included 2013 older adults, with 39.1% showing low cognitive performance and 12.7% having COPD. Those with low cognitive performance were older, less educated, had lower income, were more likely to be racial/ethnic minorities, and had a history of cardiovascular diseases (CVD); they were also more likely to have COPD or chronic kidney disease (CKD). The adjusted hazard ratio for respiratory-related mortality risk was highest for individuals with both COPD and low cognitive performance (hazards ratio = 8.53), people with COPD alone also had a higher respiratory-related mortality risk (hazards ratio = 4.92), but low cognitive performance alone did not significantly increase respiratory-related mortality risk.

CONCLUSIONS

These findings provide clearer insights into how cognitive impairment affects mortality risk in older adults with COPD and we discuss potential strategies to address this dual chronic health challenge effectively.

The application effect of a pulmonary rehabilitation program based on empowerment theory for patients with COPD combined with heart failure

BACKGROUND

Chronic obstructive pulmonary disease (COPD) and heart failure are often coexisting conditions that can severely impact patients' cardiopulmonary function and quality of life. Pulmonary rehabilitation programs, particularly those based on empowerment theory, may improve clinical outcomes by enhancing self-efficacy and promoting patient engagement.

METHODS

A total of 70 patients with COPD and heart failure admitted to our hospital's respiratory department from January 1, 2023, to April 31, 2024, were randomly assigned to either a control group (n = 35) or an observation group (n = 35). The control group received routine care, while the observation group underwent an empowerment-based pulmonary rehabilitation program in addition to routine care for 4 weeks. Lung function (forced vital capacity, forced expiratory volume in 1 second, maximum voluntary ventilation), arterial blood gas levels (partial pressure of carbon dioxide, partial pressure of oxygen, and arterial oxygen saturation), cardiac function (left ventricular ejection fraction and serum brain natriuretic peptide), cardiopulmonary function (heart rate, respiratory rate, and 6-minute walk test), self-efficacy, and rehabilitation compliance were measured before and after the intervention.

RESULTS

There were no significant differences between the groups before the intervention (P > 0.05). After the intervention, the observation group exhibited significant improvements in lung function, arterial blood gas levels, cardiac and cardiopulmonary function, and self-efficacy scores compared with the control group (P < 0.05). Rehabilitation compliance was also significantly higher in the observation group (P < 0.05).

CONCLUSION

An empowerment-based pulmonary rehabilitation program effectively improves rehabilitation compliance, lung and heart function, and self-efficacy in COPD patients with heart failure, suggesting it has strong potential for clinical application.

A Scoping Review of Factor-Related Cognitive Impairment in Interstitial Lung Disease

Understanding the risk factors for cognitive impairment in interstitial lung disease (ILD) can help guide disease management tailored to cognitive function. However, no review articles or randomized controlled trial articles have been found for cognitive impairment in ILD. This scoping review aimed to systematically map studies on factor-related cognitive impairment in ILD and organize current knowledge. Literature on cognitive impairment in ILD was retrieved from PubMed, Scopus, and EBSCO and manually searched using Google. Three researchers screened the relevant literature. Six studies were extracted: four were case-control studies; one was a cross-sectional study; and one was a prospective cohort study. The extracted literature lacked studies with a high level of evidence and only reported factor-related cognitive impairment in ILD, not risk factors. Factors related to cognitive impairment were carbon monoxide pulmonary diffusing capacity, FEV1/FVC, hospitalization for lung transplantation, delirium during hospitalization, apnea-hypopnea index and Epworth sleepiness scale scores, idiopathic pulmonary fibrosis, abnormal pulmonary artery pressure, hypoxemia, post-exercise arterial blood oxygen partial pressure and heart rate, and six-minute walk test results. This scoping review presents the current knowledge on the risk factors for cognitive dysfunction in ILD. The extracted literature did not include reports on the risk factors for cognitive impairment in ILD and was limited to reports on related factors. Building evidence on this topic is desirable for understanding the risk factors for cognitive impairment in patients with ILD.

A Multicenter Study of COPD and Cognitive Impairment: Unraveling the Interplay of Quantitative CT, Lung Function, HIF-1α, and Clinical Variables

Purpose

The exact link between cognitive impairment (CI) and chronic obstructive pulmonary disease (COPD) is still limited. Thus, we aim to find the relationship and interaction of quantitative CT (QCT), lung function, HIF-1α, and clinical factors with the development of CI among COPD patients.

Patients and Methods

A cross-sectional multicentre study was conducted from January 2022 to December 2023. We collected clinical data, spirometry, CT images, and venous blood samples from 114 COPD participants. Cognitive impairment assessment using the Montreal Cognitive Assessment Indonesian version (MoCA-Ina) with a cutoff value 26. The QCT analysis consists of lung density, airway wall thickness, pulmonary artery-to-aorta ratio (PA:A), and pectoralis muscles using 3D Slicer software. Serum HIF-1α analysis was performed using ELISA.

Results

We found significant differences between %LAA-950, age, COPD duration, BMI, FEV1 pp, and FEV1/FVC among GOLD grades I-IV. Only education duration was found to correlate with CI (r = 0.40; p < 0.001). We found no significant difference in HIF-1α among GOLD grades (p = 0.149) and no correlation between HIF-1α and CI (p = 0.105). From multiple linear regression, we observed that the MoCA-Ina score was influenced mainly by %LAA-950 (p = 0.02) and education duration (p = 0.01). The path analysis model showed both %LAA and education duration directly and indirectly through FEV1 pp contributing to CI.

Conclusion

We conclude that the utilization of QCT parameters is beneficial as it can identify abnormalities and contribute to the development of CI, indicating its potential utility in clinical decision-making. The MoCA-Ina score in COPD is mainly affected by %LAA-950 and education duration. Contrary to expectations, this study concludes that HIF-1α does not affect CI among COPD patients.

Protective effects of paeonol against cognitive impairment in lung diseases

Pulmonary inflammation may lead to neuroinflammation resulting in neurological dysfunction, and it is associated with a variety of acute and chronic lung diseases. Paeonol is a herbal phenolic compound with anti-inflammatory and anti-oxidative properties. The aim of this study is to understand the beneficial effects of paeonol on cognitive impairment, pulmonary inflammation and its underlying mechanisms. Pulmonary inflammation-associated cognitive deficit was observed in TNFα-stimulated mice, and paeonol mitigated the cognitive impairment by reducing the expressions of interleukin (IL)-1β, IL-6, and NOD-like receptor family pyrin domain-containing 3 (NLRP3) in hippocampus. Moreover, elevated plasma miR-34c-5p in lung-inflamed mice was also reduced by paeonol. Pulmonary inflammation induced by intratracheal instillation of TNFα in mice resulted in immune cells infiltration in bronchoalveolar lavage fluid, pulmonary edema, and acute fibrosis, and these inflammatory responses were alleviated by paeonol orally. In MH-S alveolar macrophages, tumor necrosis factor (TNF) α- and phorbol myristate acetate (PMA)-induced inflammasome activation was ameliorated by paeonol. In addition, the expressions of antioxidants were elevated by paeonol, and reactive oxygen species production was reduced. In this study, paeonol demonstrates protective effects against cognitive deficits and pulmonary inflammation by exerting anti-inflammatory and anti-oxidative properties, suggesting a powerful benefit as a potential therapeutic agent.

Dementia and Multimorbidity Trends in Al-Baha, Saudi Arabia: An Analytical Retrospective Study Using Records-Based Data

BACKGROUND

The prevalence of dementia is escalating significantly, posing a substantial societal burden. Currently, there exists a dearth of comprehensive health data about dementia patients in Saudi Arabia, particularly within Al-Baha City.

METHODS

A retrospective case-series study was undertaken to ascertain the prevalence of dementia within the populace of the Al-Baha region, Kingdom of Saudi Arabia. This investigation utilized hospital-based records encompassing individuals exhibiting symptoms or diagnosed with dementia and its related forms across the Al-Baha region. Furthermore, the study aimed to evaluate the burden of comorbidities among dementia patients and document the pharmacological therapeutic interventions administered to manage dementia and its associated concurrent health conditions.

RESULTS

Our investigation explored the prevalence rates of various forms of dementia and the accompanying comorbidities among affected individuals. The study spanned from August 2020 to August 2023. Our study encompassed 407 patients diagnosed with Alzheimer's disease (AD), Parkinson's disease, vascular dementia (VaD), or other forms of dementia who were either admitted to or attended tertiary hospitals in Al-Baha. Assessment of the comorbidity burden was conducted using the Charlson Comorbidity Index (CCI). Our findings revealed that among these patients, 13.3% presented with AD, 23.6% with VaD, 33.4% with Parkinson's disease, 15.75% with amnesia, and 14.0% with other types of dementia. The spectrum of comorbidities observed among dementia patients encompassed various conditions, with diabetes mellitus emerging as the predominant comorbidity (19.1%), followed by hypertension (16.4%). Additionally, manifestations of depression were noted in 14% of patients, while 9.82% suffered from paralysis. Chronic conditions such as cancer, chronic obstructive pulmonary disorder (COPD), and cervical spondylosis were also observed among individuals afflicted with dementia and its varied forms. Statistically significant correlations were established between gender, age, nationality, comorbidities, and the prevalence of dementia. Therapeutic interventions in the form of pharmacological treatments were prescribed for dementia patients with comorbidities. Commonly administered medications included Amlod (6.3%), Amlodipine (6.6%), Amlor (5.8%), Aspirin (10.5%), chemotherapeutic drugs (4.4%), Glipizide (8.5%), Lantus (11.3%), Levodopa (23.5%), Metformin (7.8%), acetylcholinesterase inhibitors (6.8%), and Pulmicort (7.86%). These medications aimed to alleviate symptoms associated with dementia and its accompanying comorbidities.

CONCLUSIONS

Our investigation underscores the substantial burden of comorbidities experienced by dementia patients. These findings offer crucial insights into the overall health status of individuals grappling with dementia, serving as a catalyst for increased awareness among clinicians and policymakers. Such awareness can drive improvements in medical care and support frameworks tailored to the specific needs of dementia patients.